Engineered human tmpk/AZT as a novel enzyme/prodrug axis for suicide gene therapy

Molecular Therapy

Volumn 15, Issue 5, 2007, Pages 962-970

  Sato, Takeya ^a   Neschadim, Anton ^a,b   Konrad, Manfred ^c   Fowler, Daniel H ^d   Lavie, Arnon ^e   Medin, Jeffrey A ^a,b  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c MAX PLANCK INSTITUTE FOR BIOPHYSICAL CHEMISTRY   (Germany)

^d NATIONAL CANCER INSTITUTE   (United States)

^e UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; LENTIVIRUS VECTOR; PHOSPHOTRANSFERASE; THYMIDYLATE KINASE; UNCLASSIFIED DRUG; ZIDOVUDINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BLOOD TOXICITY; CELL DIVISION; CELL MEMBRANE POTENTIAL; CELL STRAIN K 562; CONTROLLED STUDY; CYTOTOXICITY; ENZYME ACTIVATION; ENZYME PRODRUG THERAPY; GENETIC ENGINEERING; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LEUKEMIA; LEUKEMIA CELL LINE; LOW DRUG DOSE; MITOCHONDRIAL MEMBRANE; NEPHROTOXICITY; NONHUMAN; SAFETY; SCID MOUSE; SUICIDE GENE THERAPY; T LYMPHOCYTE; TUMOR GROWTH; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; ANTIGENS, CD19; ANTIMETABOLITES; APOPTOSIS; BLOTTING, WESTERN; CASPASE 3; CELL LINE, TUMOR; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; FLOW CYTOMETRY; GENE THERAPY; GENES, TRANSGENIC, SUICIDE; GENETIC VECTORS; HUMANS; JURKAT CELLS; K562 CELLS; MALE; MICE; MICE, INBRED NOD; MICE, SCID; NUCLEOSIDE-PHOSPHATE KINASE; PRODRUGS; T-LYMPHOCYTES; TRANSFECTION; ZIDOVUDINE;

MURINAE; MUS;

EID: 34247194881     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.sj.6300122     Document Type: Article

References (49)

1. Hacien-Bey-Abina, S, Von Kalle, C, Schmidt, M, McCormack, MP, Wulffraat, N, Leboulch, P et al. (2003). LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 302: 415-419.
2. Roy, NS, Cleren, C, Singh, SK, Yang, L, Beal, MF and Goldman, SA (2006). Functional engraftment of human ES cell-derived dopaminergic neurons enriched by coculture with telomerase-immortalized midbrain astrocytes. Nat Med 12: 1259-1268.
3. Nishiyama, Y and Rapp, F (1979). Anticellular effects of 9-(2-hydroxyethoxymethyl) guanine against herpes simplex virus-transformed cells. J Gen Virol 45: 227-230.
4. Moolten, FL (1986). Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: Paradigm for a prospective cancer control strategy. Cancer Res 46: 5276-5281.
5. Mesnil, M and Yamasaki, H (2000). Bystander effect in herpes simplex virus-thymidine kinase/ganciclovir cancer gene therapy: Role of gap-junctional intercellular communication. Cancer Res 60: 3989-3999.
6. Kokoris, MS and Black, ME (2002). Characterization of herpes simplex virus type 1 thymidine kinase mutants engineered for improved ganciclovir or acyclovir activity. Protein Sci 11: 2267-2272.
7. Qasim, W, Thrasher, AJ, Buddle, J, Kinnon, C, Black, ME and Gaspar, HB (2002). T cell transduction and suicide with an enhanced mutant thymidine kinase. Gene Ther 9: 824-827.
8. Riddell, SR, Elliott, M, Lewinsohn, DA, Gilbert MJ, Wilson, L, Manley, SA et al. (1996). T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-Infected patients. Nat Med 2: 216-223.
9. Berger, C, Flowers, ME, Warren, EH and Riddell, SR (2006). Analysis of transgene-specific immune responses that limit the in vivo persistence of adoptively transferred HSV-TK-modified donor T cells after allogeneic hematopoietic cell transplantation. Blood 107 2294-2302.
10. Van Rompay, AR, Johansson, M and Karlsson, A (2000). Phosphorylation of nucleosides and nucleoside analogs by mammalian nucleoside monophosphate kinases. Pharmacol Ther 87: 189-198.
11. Furman, PA, Fyfe, JA, St Clair, MH, Weinhold, K, Rideout, JL, Freeman, GA et al. (1986). Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction of the 5'-triphosphate with human immunodeficiency virus reverse transcriptase. Proc Natl Acad Sci USA 83: 8333-8337.
12. St Clair, MH, Richards, CA, Spector, T, Weinhold, KJ, Miller, WH, Langlois, AJ et al. (1987). 3'-Azido-3'-deoxythymidine triphosphate as an inhibitor and substrate of purified human immunodeficiency virus reverse transcriptase. Antimicrob Agents Chemother 31: 1972-1977.
13. Johnson, AA, Ray, AS, Hanes, J, Suo, Z, Colacino, JM, Anderson, KS et al. (2001). Toxicity of antiviral nucleoside analogs and the human mitochondrial DNA polymerase. J Biol Chem 276: 40847-40857.
14. Lavie, A, Schlichting, I, Vetter, IR, Konrad, M, Reinstein, J and Goody, RS (1997). The bottleneck in AZT activation. Nat Med 3: 922-924.
15. Brundiers, R, Lavie, A, Veit, T, Reinstein, J, Schlichting, I, Ostermann, N et al. (1999). Modifying human thymidylate kinase to potentiate azidothymidine activation. J Biol Chem 274: 35289-35292.
16. Ostermann, N, Lavie, A, Padiyar, S, Brundiers, R, Veit T, Reinstein, J et al. (2000). Potentiating AZT activation: Structures of wild-type and mutant human thymidylate kinase suggest reasons for the mutants' improved kinetics with the HIV prodrug metabolite AZTMP. J Mol Biol 304: 43-53.
17. Naldini, L, Blomer, U, Gallay, P, Ory, D, Mulligan, R, Gage, FH et al. (1996). In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 272; 263-267.
18. Yoshimitsu, M, Sato, T, Tao, K, Walia, JS, Rasaiah, VI, Sleep, GT et al. (2004). Bioluminescent imaging of a marking transgene and correction of Fabry mice by neonatal injection of recombinant lentiviral vectors. Proc Natl Acad Sci USA 101: 16909-16914.
19. Medin, JA and Karlsson, S (1997). Selection of retrovirally transduced cells to enhance the efficiency of gene therapy. Proc Assoc Am Physicians 109: 111-119.
20. Sadelain, M and Riviere, I (2002). Sturm und drang over suicidal lymphocytes. Mol Ther 5: 655-657.
21. Migita, M, Medin, JA, Pawliuk, R, Jacobson, S, Nagle, JW, Anderson, S et al. (1995). Selection of transduced CD34+ progenitors and enzymatic correction of cells from Gaucher patients, with bicistronic vectors. Proc Natl Acad Sci USA 92: 12075-12079.
22. Medin, JA, Migita, M, Pawliuk, R, Jacobson, S, Amiri, M, Kluepfel-Stahl, S et al. (1996). A bicistronic therapeutic retroviral vector enables sorting of transduced CD34+ cells and corrects the enzyme deficiency in cells from Gaucher patients. Blood 87: 1754-1762.
23. Qin, G, Takenaka, T, Telsch, K, Kelley, L, Howard, T, Levade, T et al (2001). Preselective gene therapy for Fabry disease. Proc Natl Acad Sci USA 98: 3428-3433.
24. Siatskas, C, Underwood, J, Ramezani, A, Hawley, RG and Medin, JA (2005). Specific pharmacological dimerization of KDR in lentivirally transduced human hematopoietic cells activates anti-apoptotic and proliferative mechanisms. FASEB J 19: 1752-1754.
25. Medin, JA, Liang, SB, Hou, JW, Kelley, LS, Peace, DJ and Fowler, DH (2005). Efficient transfer of PSA and PSMA cDNAs into DCs generates antibody and T cell antitumor responses in vivo. Cancer Gene Ther 12: 540-551.
26. Li, Z, Dullmann, J, Schiedlmeier, B, Schmidt, M, von Kalle, C, Meyer, J et al. (2002). Murine leukemia induced by retroviral gene marking. Science 296: 497.
27. Doody, GM, Dempsey, PW and Fearon, DT (1996). Activation of B lymphocytes: Integrating signals from CD19, CD22 and Fc gamma Rllb1. Curr Opin Immunol 8: 378-382.
28. Fujimoto, M, Poe, JC, Hasegawa, M and Tedder, TF (2000). CD19 regulates intrinsic B lymphocyte signal transduction and activation through a novel mechanism of processive amplification. Immunol Res 22: 281-298.
29. Tedder, TF, Zhou, LJ and Engel, P (1994). The CD19/CD21 signal transduction complex of B lymphocytes. Immunol Today 15: 437-442.
30. Sato, S, Miller, AS, Howard, MC and Tedder, TF (1997). Regulation of B lymphocyte development and activation by the CD19/CD21 /CD81/Leu 13 complex requires the cytoplasmic domain of CD19. J Immunol 159 3278-3287.
31. Greco, O and Dachs, GU (2001). Gene directed enzyme/prodrug therapy of cancer: Historical appraisal and future prospectives. J Cell Physiol 187: 22-36.
32. Mizuguchi, H, Xu, Z, Ishii-Watabe, A, Uchida, E and Hayakawa, T (2000). IRES-dependent second gene expression is significantly lower than cap-dependent first gene expression in a bicistronic vector. Mol Ther 1: 376-382.
33. Coplan, NL and Bruno, MS (1989). Acquired immunodeficiency syndrome and heart disease: The present and the future. Am Heart J 1117: 1175-1177.
34. Sales, SD, Hoggard, PG, Sunderland, D, Khoo, S, Hart CA and Back, DJ (2001). Zidovudine phosphorylation and mitochondrial toxicity in vitro. Toxicol Appl Pharmacol 177: 54-58.
35. Masini, A, Scotti, C, Calligaro, A, Cazzalini, O, Stivala, LA, Bianchi, L et al. (1999). Zidovudine-induced experimental.myopathy: Dual mechanism of mitochondrial damage. J Neurol Sci 166: 131-140.
36. Smiley, ST, Reers, M, Mottola-Hartshorn, C, Lin, M, Chen, A, Smith, TW et al. (1991). Intracellular heterogeneity in mitochondrial membrane potentials revealed by a J-aggregate-forming lipophilic cation JC-1. Proc Natl Acad Sci USA 88: 3671-3675.
37. Green, DR and Reed, JC (1998). Mitochondria and apoptosis. Science 281: 1309-1312.
38. Omar, RF, Gourde, P, Desormeaux, A, Tremblay, M, Beauchamp, D and Bergeron, MG (1996). In vivo toxicity of foscarnet and zidovudine given alone or in combination. Toxicol Appl Pharmacol 139 324-332.
39. Cazzalini, O, Lazze, MC, Iamele, L, Stivala, LA, Bianchi, L, Vaghi, P et al. (2001). Early effects of AZT on mitochondrial functions in the absence of mitochondrial DNA depletion in rat myotubes. Biochem Pharmacol 62: 893-902.
40. McKee, EE, Bentley, AT, Hatch, M, Gingerich, J and Susan-Resiga, D (2004). Phosphorylation of thymidine and AZT in heart mitochondria: elucidation of a novel mechanism of AZT cardiotoxicity. Cardiovasc Toxicol 4: 155-167.
41. Mahmoud, MS, Fujii, R, Ishikawa, H and Kawano, MM (1999). Enforced CD19 expression leads to growth inhibition and reduced tumorigenicity. Blood 94: 3551-3558.
42. Bonini, C, Ferrari, G, Verzeletti, S, Servida, P, Zappone, E, Ruggieri, L et al. (1997). HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science 276: 1719-1724.
43. Cohen, JL, Boyer, O, Salomon, B, Onclercq, R, Charlotte, F, Bruel, S et al. (1997). Prevention of graft-versus-host disease in mice using a suicide gene expressed in T lymphocytes. Blood 89: 4636-4645.
44. Spencer, DM (2000). Developments in suicide genes for preclinical and clinical applications. Curr Opin Mol Ther 2: 433-440.
45. Lal, S, Lauer, UM, Niethammer, D, Beck, JF and Schlegel, PG (2000). Suicide genes: Past, present and future perspectives. Immunol Today 21: 48-54.
46. Kershaw, MH, Teng, MW, Smyth, MJ and Darcy, PK (2005). Supernatural T cells: Genetic modification of T cells for cancer therapy. Nat Rev Immunol 5: 928-940.
47. Chow, HH, Li, P, Brookshier, G and Tang, Y (1997). In vivo tissue disposition of 3'-azido-3'-deoxythymidine and its anabolites in control and retrovirus-infected mice. Drug Metab Dispos 25: 412-422.
48. Jung, U, Foley, JE, Erdmann, AA, Eckhaus, MA and Fowler, DH (2003). CD3/ CD28-costimulated T1 and T2 subsets: Differential in vivo allosensitization generates distinct GVT and GVHD effects. Blood 102: 3439-3446.
49. Weichold, FF, Jiang, YZ, Dunn, DE, Bloom, M, Malkovska, V, Hensel, NF et al. (1997). Regulation of a graft-versus-leukemia effect by major histocompatibility complex class II molecules on leukemia cells: HLA-DR1 expression renders K562 cell tumors resistant to adoptively transferred lymphocytes in severe combined immunodeficiency mice/nonobese diabetic mice. Blood 90: 4553-4558.